Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' EBIT Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • As of Q3 2025, Corcept Therapeutics' EBIT Margin stood at 4.92%, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • Corcept Therapeutics' EBIT Margin's 5-year high stood at 37.69% during Q3 2021, with a 5-year trough of 2.17% in Q1 2025.
  • Its 5-year average for EBIT Margin is 22.97%, with a median of 24.72% in 2021.
  • As far as peak fluctuations go, Corcept Therapeutics' EBIT Margin skyrocketed by 90600bps in 2021, and later plummeted by -206100bps in 2025.
  • Over the past 5 years, Corcept Therapeutics' EBIT Margin (Quarter) stood at 37.1% in 2021, then plummeted by -41bps to 21.83% in 2022, then rose by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then crashed by -65bps to 4.92% in 2025.
  • Its EBIT Margin stands at 4.92% for Q3 2025, versus 13.72% for Q2 2025 and 2.17% for Q1 2025.